Hyperacute treatment initiation in neuroprotective agent stroke trials

Journal of Stroke and Cerebrovascular Diseases

Volumn 13, Issue 3, 2004, Pages 109-112

  Ferguson, Katrina N ^a   Kidwell, Chelsea S ^a   Starkman, Sidney ^a   Saver, Jeffrey L ^a,b  

^a UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute stroke; cerebral infarction; clinical trials; focal cerebral ischemia; neuroprotection

Indexed keywords

NEUROPROTECTIVE AGENT;

BRAIN INFARCTION; DATA ANALYSIS; DRUG SCREENING; EARLY DIAGNOSIS; HUMAN; INFORMATION RETRIEVAL; NEUROPROTECTION; POSTAL MAIL; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; STROKE; SYSTEMATIC REVIEW;

EID: 3042796960     PISSN: 10523057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2004.04.001     Document Type: Article

References (16)

1. Kidwell C.S., Liebeskind D.S., Starkman S., et al. Trends in acute ischemic stroke trials through the 20th century. Stroke. 32:2001;1349-1359
2. Heiss W.D., Thiel A., Grond M., et al. Which targets are relevant for therapy of acute ischemic stroke? Stroke. 30:1999;1486-1489
3. Grotta J. Neuroprotection is unlikely to be effective in humans using current trial designs. Stroke. 33:2002;306-307
4. Hennerici M., Kramer G., North P.M., et al. Nimodipine in the treatment of acute MCA ischemic stroke. Cerebrovasc Dis. 4:1994;189-193
5. RANTTAS Investigators. A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS). Stroke. 27:1996;1453-1458
6. Yamaguchi T., Sano K., Takakura K., et al. Ebselen in acute ischemic stroke A placebo-controlled, double-blind clinical trial; Ebselen study group. Stroke. 29:1998;12-17
7. Pulsinelli W., Mann M., Welch M., et al. Fosphenytoin in acute ischemic stroke Efficacy results. Neurology. 52:(suppl):1999;A384
8. Lees K.R., Asplund K., Carolei A., et al. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke A randomized controlled trial; GAIN international investigators. Lancet. 355:2000;1949-1954
9. Sacco R.L., DeRosa J.T., Haley E.C. Jr, et al. Glycine antagonist in neuroprotection for patients with acute stroke GAIN Americas; a randomized controlled trial. JAMA. 285:2001;1719-1728
10. De Keyser J., Sulter G., Luiten P.G. Clinical trials with neuroprotective drugs in acute ischemic stroke Are we doing the right thing? Trends Neurosci. 22:1999;535-540
11. Gorelick P.B. Neuroprotection in acute ischaemic stroke A tale of for whom the bell tolls? Lancet. 355:2000;1925-1926
12. DeGraba T.J., Pettigrew L.C. Why do neuroprotective drugs work in animals but not humans? Neurol Clin. 18:2000;475-493
13. Lees K.R. Advances in neuroprotection trials. Eur Neurol. 45:2001;6-10
14. Ovbiagele B., Kidwell C.S., Starkman S., et al. Neuroprotective agents for the treatment of acute ischemic stroke. Curr Neurol Neurosci Rep. 3:2003;9-20
15. NINDS rt-PA Stroke Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 333:1995;1581-1587
16. Saver J.L., Kidwell C.S., Eckstein M., et al. Prehospital neuroprotective therapy for acute stroke Results of the Field Administration of Stroke Therapy-Magnesium (FAST-MAG) Pilot Trial. Stroke. 35:2004;e106-e108